Skip to main content
Search

Guide

Informing the FDA BEST Initiative

The U.S. FDA works with Optum Epidemiology to decide if drugs and vaccines are safe, including COVID-19.

The FDA Biologics Effectiveness and Safety (BEST) Initiative

The U.S. Food & Drug Administration (FDA) needs to make decisions on drug and vaccine safety and effectiveness with confidence. As a key collaborator, Optum Epidemiology generates reproducible results that inform decisions for COVID-19 vaccines. Learn more at bestinitiative.org.

Key takeaways

  • Optum Epidemiology follows strict rules to produce data to help make decisions about vaccines
  • Optum Epidemiology publicizes their findings for wide review
  • Optum uses claims, EHR records and other data to inform studies with the FDA

Related healthcare insights

View all

Article

Using epidemiological data build public confidence

See how the FDA and Optum use real-world evidence to monitor the safety and effectiveness of COVID-19 vaccines in our youngest populations.

E-book

The 6 trends shaping pharma strategies in 2024

Life sciences market experts from Optum and Advisory Board share perspectives on trends that will influence the future drug value chain.

Article

Monitoring COVID-19 vaccine safety

Discover insights from Dr. John Seeger’s recent participation at the Duke-Margolis Thirteenth Annual Sentinel Initiative Public Workshop.